SymbioCellTech Treats First Pet Dog in FDA-approved Companion Animal Trial

Written by SymbioCellTech, LLC

Under an Investigational New Animal Drug (INAD), SymbioCellTech, LLC began it’s FDA-approved companion animal trial to treat canine diabetes. The first pet dog underwent a minor outpatient procedure to administer SCT’s proprietary, first of its kind, Neo-Islet therapy into the abdomen and is recovering quite well.

SymbioCellTech, LLC
Previous

'Neo-Islets', a Major Advance Toward a Functional Cure for Type-1 Diabetes. SymbioCellTech Featured on the Cover of Stem Cells Translational Medicine
Next

SymbioCellTech recieves FDA approval to conduct pilot studies in pet dogs